Logo image of NRIX

NURIX THERAPEUTICS INC (NRIX) Stock News

NASDAQ:NRIX - Nasdaq - US67080M1036 - Common Stock - Currency: USD

11.39  -0.25 (-2.15%)

After market: 11.39 0 (0%)

NRIX Latest News, Press Relases and Analysis

News Image
17 days ago - Nurix Therapeutics, Inc.

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the...

News Image
18 days ago - Nurix Therapeutics, Inc.

Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström

Complete response achieved in CLL; overall objective response rate of 80.9% in CLL patients and 84.2% in patients with WM Bexobrutideg was well tolerated...

News Image
24 days ago - Nurix Therapeutics, Inc.

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)

SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the...

News Image
a month ago - Benzinga

Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout

Sanofi will acquire Blueprint Medicines for up to $9.5 billion, gaining Ayvakit and a promising immunology pipeline, including BLU-808 and elenestinib.

Mentions: SNY BPMC

News Image
a month ago - Yahoo Finance

Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout

Sanofi SA (NASDAQ:SNY) on Monday agreed to acquire Blueprint Medicines Corporation (NASDAQ:BPMC). The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the U.S. and the EU, and a promising advanced and early-stage immunology pipeline. Ayvakit/Ayvakyt is the only approved medicine for advanced and indolent systemic mastocytosis (ASM & ISM), a rare immunology disease, which is characterized by the accumulation and activation of aberrant mast cells

Mentions: SNY BPMC VZ DHI ...

News Image
a month ago - Nurix Therapeutics, Inc.

Sanofi Exercises License Extension Option to Nurix’s STAT6 Program

Sanofi Licenses Nurix's STAT6 program...

News Image
2 months ago - Nurix Therapeutics, Inc.

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, May 16, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the...

News Image
2 months ago - Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma

SAN FRANCISCO, May 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the...

News Image
2 months ago - Yahoo Finance

Why Nurix Therapeutics (NRIX) Is Among the Best Low Priced Biotech Stocks to Buy Now

We recently published a list of 10 Best Low Priced Biotech Stocks to Buy Now. In this article, we are going to take a look at where Nurix Therapeutics, Inc. (NASDAQ:NRIX) stands against other best low priced biotech stocks to buy now. Is Now the Time to Buy Biotech Stocks? On May 8, Michael Yee, […]

Mentions: DHI CMG

News Image
2 months ago - Nurix Therapeutics, Inc.

Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs

Nurix’s DEL-AI platform uses a first-in-class DEL Foundation Model trained on the Company’s proprietary DNA encoded library data Nurix’s DEL Foundation...

News Image
2 months ago - Nurix Therapeutics, Inc.

Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets

Nurix's lead BTK degrader, bexobrutideg, demonstrates exceptional efficiency, with a single molecule degrading approximately 10,000 copies of BTK per...

News Image
2 months ago - Nurix Therapeutics, Inc.

Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions

Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy volunteers in Q2...

News Image
3 months ago - Nurix Therapeutics, Inc.

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, April 11, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the...

News Image
3 months ago - Nurix Therapeutics, Inc.

Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

NX-5948 assigned the nonproprietary name “bexobrutideg”U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström...

News Image
3 months ago - Nurix Therapeutics, Inc.

Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases

The undisclosed target is a central regulator of inflammation that is distinct from the previously disclosed STAT6 program Nurix DEL-AI drug discovery...

News Image
3 months ago - Zacks Investment Research

Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates

Cue Biopharma (CUE) delivered earnings and revenue surprises of 18.75% and 5.40%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Mentions: CUE

News Image
3 months ago - Zacks Investment Research

Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Tops Revenue Estimates

Spero Therapeutics (SPRO) delivered earnings and revenue surprises of -8.57% and 21.32%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Mentions: SPRO

News Image
3 months ago - Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting

SAN FRANCISCO, March 25, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the...

News Image
4 months ago - Nurix Therapeutics, Inc.

Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia

First-in-class BTK degrader, NX-5948, Granted ODD for WM and assigned nonproprietary name “bexobrutideg” in newly named degrader class of drugs ...

News Image
4 months ago - Nurix Therapeutics, Inc.

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, March 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the...

News Image
4 months ago - Nurix Therapeutics, Inc.

Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D., to Its Board of Directors

Dr. Baynes has been a member of Nurix’s Medical Advisory Board since 2023 ...

News Image
4 months ago - Nurix Therapeutics, Inc.

Nurix Therapeutics to Participate in Upcoming Investor Conferences

SAN FRANCISCO, March 04, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the...

News Image
5 months ago - Nurix Therapeutics, Inc.

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the...

News Image
5 months ago - Nurix Therapeutics, Inc.

Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

SAN FRANCISCO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the...

News Image
5 months ago - Nurix Therapeutics, Inc.

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update

Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th American...

News Image
5 months ago - Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer

Mr. Northcott brings over 20 years of biopharmaceutical experience building commercial organizations and successfully commercializing novel products,...

News Image
6 months ago - Nurix Therapeutics, Inc.

Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

SAN FRANCISCO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted...

News Image
6 months ago - Nurix Therapeutics, Inc.

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia

Fast track designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenstrom’s Macroglobulinemia...

News Image
7 months ago - Nurix Therapeutics, Inc.

Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting

Durable responses are rapid and deepen on treatment as demonstrated by an initial 75.5% Objective Response Rate which increased to 84.2% in patients with...